SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-033940
Filing Date
2024-04-18
Accepted
2024-04-18 08:15:21
Documents
3
Period of Report
2024-04-18

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0204148-6k_ysbio.htm 6-K 12607
2 PRESS RELEASE - YS BIOPHARMA GRANTED PHASE I CLINICAL TRIAL LICENSE OF THERAPEUT ea020414801ex99-1_ysbio.htm EX-99.1 13425
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2525
  Complete submission text file 0001213900-24-033940.txt   30911
Mailing Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629
Business Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629 17327133678
YS Biopharma Co., Ltd. (Filer) CIK: 0001946399 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-41598 | Film No.: 24852912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)